Terms ending in 2033
Every in-force patent on CureVac AG's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,690,910 | Pharmaceutical Composition Comprising a Polymeric Carrier Cargo Complex and at Least One Protein or Peptide Antigen In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 9,683,233 | Artificial Nucleic Acid Molecules for Improved Protein or Peptide Expression In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,047,375 | Artificial Nucleic Acid Molecules In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,738,306 | Artificial Nucleic Acid Molecules for Improved Protein or Peptide Expression In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 11,458,193 | Combination of Vaccination and Inhibition of MHC Class I Restricted Antigen Presentation In force · Medium confidence | Curevac SE | In force | Medium confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.